canceldeath

Acarbose

Experimental off label · Evidence and recent research

Notify me when meaningful evidence changes.

Where things stand

Acarbose has extended lifespan in the National Institute on Aging’s mouse testing program, making it an interesting candidate for ageing research. Repeated animal results help justify investigation, but do not determine whether a diabetes medicine benefits people without diabetes or extends human life. Human clinical outcomes are the important next test of the longevity hypothesis. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.

AI-written overview · not expert-reviewed · Background sources checked Sep 23, 2026 · Recent updates cover the last 30 days of this collection. A new report does not automatically change the evidence assessment.

⚠ Prescription or off-label use

Approved for diabetes. Use for longevity is off-label.

NIA: Interventions Testing Program ↗

Regulatory status
Approved other indication
Availability
Prescription only
Category
Experimental off label
Human results verified here
0

Evidence collection is needs review. 0 approved assessments; 9 assessments awaiting review; 1 published studies with verified results. Safety: not assessed.

Methodology →

A numeric breakdown will be available after baseline review. Safety is not yet assessed.

Evidence events affecting this intervention

Browse all evidence →
Assessment pending

Linum strictum seed oil showed α-amylase inhibition comparable to acarbose in in vitro testing.

This in vitro study characterized the fatty acid composition of Linum strictum seed oil and tested its biological activities. The oil's α-amylase inhibition reached 85.98% with an IC50 of 0.0134 mg/mL, which the authors report as comparable to acarbose. The study also found antibacterial activity against several strains, >70% biofilm inhibition against A. baumannii, and anticoagulant effects.

IN VITRO1mo

The 25 most recent recorded changes, including corrections and backfill

Historical record correctionSource updated; previous assessment withdrawn

No published human results verified in this collection yet

IN VITRO
Chemistry & Biodiversity · Sep 1, 2026 · Antibacterial: MIC = 1.25 mg/mL (against E. faecalis ATCC 29212 and A. baumannii strains A2553 and A722); MIC = 5 mg/mL (S. aureus strains). Biofilm inhibition: >70% against A. baumannii at 2×MIC. Anticoagulant: PT = 16.4 s; aPTT = 81.6 s. α-Amylase inhibition: 85.98% (IC50 = 0.0134 mg/mL)

Testable statements and where the evidence stands

Acarbose inhibits α-amylaseSynthesis pending0 for · 0 against